Registry Platform Colorectal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Colorectal Cancer Metastatic
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
AZURITE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic colorectal cancer in Germany. The registry will follow patients for up to three years. It will iden...
AZURITE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic colorectal cancer in Germany. The registry will follow patients for up to three years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life (HRQoL) will be evaluated for up to three years.
Tracking Information
- NCT #
- NCT04867525
- Collaborators
- Not Provided
- Investigators
- Study Chair: Nicolas Graf, PD Dr. Deggendorf Study Chair: Frank Kullmann, Prof. Dr. Weiden i.d.O. Study Chair: Patrick Marschner Freiburg i.Br. Study Chair: Marlies Michl, PD Dr. München Study Chair: Jens Neumann, Prof. Dr. München Study Chair: Roland Schnell, PD Dr. Frechen Study Chair: Sebastian Stintzing, Prof. Dr. Berlin
Get Well Soon